Janus kinase inhibitors for alopecia areata

Brett A King; Brittany G Craiglow

doi:10.1016/j.jaad.2023.05.049

Janus kinase inhibitors for alopecia areata

J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049.

Authors

Brett A King¹, Brittany G Craiglow²

Affiliations

¹ Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut. Electronic address: brett.king@yale.edu.
² Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut.

PMID: 37591562
DOI: 10.1016/j.jaad.2023.05.049

Abstract

Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection.

Keywords: JAK; JAK inhibitor; Janus kinase; Janus kinase inhibitor; alopecia; alopecia areata; alopecia totalis; alopecia universalis; baricitinib; deuruxolitinib; hair loss; ritlecitinib; ruxolitinib; tofacitinib.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Alopecia Areata* / drug therapy
Clinical Trials, Phase III as Topic
Humans
Janus Kinase Inhibitors* / therapeutic use
Patient Selection

Substances

Janus Kinase Inhibitors

Supplementary concepts

Diffuse alopecia